Pancreatic Neuroendocrine Tumour

Gender Neutral
Type Module
Testing Phase III - in development
Principal investigator(s)
John Ramage
Hampshire Hospitals NHS Foundation Trust
Basingstoke, United Kingdom
Study coordinator(s)
Liz Friend
Hampshire Hospitals NHS Foundation Trust
Basingstoke, United Kingdom

Project summary

Neuroendocrine Tumours (NETs) can arise from most parts of the body but commonest are Lung, Pancreas and Gut. The EORTC QLQ-GINET21 module for patients with gastrointestinal neuroendocrine tumours was fully validated and published. Patients with pNET were included in the GINET group but their tumours have differences to other GINET.

The aim of the study  is to develop  a questionnaire  to assess quality of life in patients with Neuroendocrine Tumour of pancreatic origin (pNET), with particular respect to functioning pNET, that are not already assessed by the QLQ-C30. The resultant questionnaire will consist of questions relevant for non-functioning, insulinoma and gastrinoma patients.

The current EORTC guidelines for adapting the existing GINET21 module were used and study sites included those from UK, Europe and a non-European site for cross cultural applicability.

Achievements

Recruitment has recently been completed for phase 3.

Patients were recruited from 16 study sites which included UK, Southern Europe, Eastern Europe, Northern Europe and Non-European.

Phase 1 to 3 recruitment completed

Future plans

Next steps are analyzing the data. Then, submitting the phase 3 report to the EORTC.

For patients

The aim of the study is to develop a questionnaire to assess quality of life in patients with Pancreatic Neuroendocrine Tumour sub types -non-functioning, insulinoma and gastrinoma.